A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects with or without HIV Infection

T
Teresa Batteiger, MD

Primary Investigator

Overview

The purposes of this study are to compare the effect of 1 dose of Benzathine Penicillin G (BPG) to 3 weekly doses of BPG in all subjects; and to determine whether the effects of 1 dose of BPG or 3 weekly doses of BPG are different in HIV-infected and HIV-uninfected subjects.

Description

Adults 18 years of age and older are needed for a study assessing syphilis treatment. This study is being conducted by Dr. Teresa Batteiger at Indiana University School of Medicine. The study takes place in the Bell Flower Clinic of the Fifth Third Office Building, next to Eskenazi Hospital.

This study will compare the effect of one dose to three doses (one dose a week for three weeks in a row) of medication normally given for treatment of Syphilis in individuals with or without HIV infection. Volunteers must have early syphilis but have not been treated yet. You will be paid for your participation. The total duration of participation is 12 months, with 8 visits over that time. Risks will be disclosed prior to study enrollment.

For information or to see if you qualify, call Lora at 317-274-8453.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    syphilis,HIV,1804212716
  • Age: Between 18 Years - 100 Years
  • Gender: All

Adults 18 years of age and older

Volunteers must have early syphilis but have not been treated yet.
Additional Information:

Updated on 13 Apr 2023. Study ID: 1804212716

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center